Vasodilators in chronic heart failure
著者
書誌事項
Vasodilators in chronic heart failure
Springer-Verlag, 1983
大学図書館所蔵 全3件
  青森
  岩手
  宮城
  秋田
  山形
  福島
  茨城
  栃木
  群馬
  埼玉
  千葉
  東京
  神奈川
  新潟
  富山
  石川
  福井
  山梨
  長野
  岐阜
  静岡
  愛知
  三重
  滋賀
  京都
  大阪
  兵庫
  奈良
  和歌山
  鳥取
  島根
  岡山
  広島
  山口
  徳島
  香川
  愛媛
  高知
  福岡
  佐賀
  長崎
  熊本
  大分
  宮崎
  鹿児島
  沖縄
  韓国
  中国
  タイ
  イギリス
  ドイツ
  スイス
  フランス
  ベルギー
  オランダ
  スウェーデン
  ノルウェー
  アメリカ
注記
Proceedings of a symposium organized by the Deutsche Gesellschaft für Herz- und Kreislaufforschung in Hinterzarten, Germany in June 1981
Includes bibliographical references and index
内容説明・目次
内容説明
The therapeutic principle of pharmacological vasodilation in congestive heart failure is based upon established physiological and pathophysiological mechanisms and has been proved to be effective and useful. In acute heart failure this method of treatment has assumed importance as the first measure to be taken. In chronic heart failure a sizeable increase in cardiac output can be achieved with a number of vasodilating drugs. This effect can be maintained over several weeks or months. The adjustments of the heart and the circulation to the arteriolar and/or venous unloading effect of vasodilatation in the situation of acute and chronic heart failure are well understood. However, long-term adaptations of the organism to the vasodilat- ing intervention have not yet fully been described. In many instances of chronic ad- ministration of vasodilators, attenuation of the response has been observed. The mech- anisms responsible have not been fully elucidated, nor has there been a satisfactory demonstration of improved exercise performance or of life expectancy under this mode of treatment in the patient with chronic heart failure.
In an attempt better to understand the pathophysiological mechanisms of chronic congestive heart failure as they apply to long-term treatment with vasodilators, the working group on vasodilator therapy of the Deutsche Gesellschaft fUr Herz- und Kreis- laufforschung has assembled a group of physiologists, pharmacologists, and clinicians. The Proceedings of their Symposium held in Hinterzarten in June 1981 are presented here.
目次
I. Physiology.- Vasoconstrictor Mechanisms and the Effects of Nitrates.- Functional and Metabolic Consequences of Chronic Alterations in Preload and Afterload in the Hypertrophied and Dilated Heart.- The Sympathetic Nervous System in Chronic Heart Failure and Its Response to Vasodilator Therapy.- Regulation of Renal Hemodynamics in Congestive Heart Failure.- The Renin-Angiotensin-Aldosterone System in Congestive Heart Failure.- Endogenous Catecholamines Under Chronic Vasodilator Treatment.- Effects of Hydralazine and Isosorbide Dinitrate on Vasoconstrictor Mechanisms in Patients with Heart Failure.- II. Pharmacology.- Cellular Mechanism of Action of Directly Acting Vasodilator Drugs.- Pharmacokinetics of Nitrates.- Isosorbide Dinitrate: Pharmacokinetics After Intravenous Administration.- Prazosin and ?-Blocking Agents.- III. Clinical Experience.- Promises and Disappointments of Vasodilator Treatment of Chronic Heart Failure.- Nitrates in Chronic Heart Failure.- The Long-Term Effects of Dihydralazine and Hydralazine on Intractable Cardiac Failure.- The Use for Hydralazine in Chronic Cardiac Failure: Results and Unanswered Questions.- Prazosin Therapy in Severe Chronic Congestive Heart Failure.- Early Experience with Captopril in Congestive Heart Failure.- Acute Effect of Nifedipine on Left Ventricular Performance at Rest and During Exercise in Patients with Left Ventricular Dysfunction.- Treatment of Congestive Heart Failure with Dipyridamole.- Therapeutic Agents with Combined Inotropic and Vasodilating Properties.- Hemodynamic Effects of Combined Inotropic and Vasodilator Drugs in Severe Congestive Heart Failure: Hydralazine and Prenalterol.- AR-L 115 BS, a Substance with Inotropic and Vasodilating Effects.- Efficacy of AR-L 115 BS on Hemodynamics, Contractility, and Myocardial Oxygen Consumption in Man.- Treatment of Cardiac Failure with AR-L 115 BS.- IV. Conception and Planning of Future Studies.- Can Vasodilator Treatment Improve Life Expectancy and Physical Performance Heart Failure?.- Vasodilators in Chronic Heart Failure: Problems of Design and Analysis of Controlled Clinical Trials.
「Nielsen BookData」 より